Trials / Completed
CompletedNCT04520971
Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes
Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes: a Randomized Controlled Trial: the CRISTAL Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Multi-centric open-label randomized controlled trial (RCT) with 11 Belgian centers and one Dutch center in pregnant women with type 1 diabetes to assess safety, efficacy, feasibility and cost-effectiveness of 780 MiniMed Medtronic hybrid closed-loop insulin system (intervention group) compared to standard of care therapy (control group).
Detailed description
Women will be recruited with a singleton pregnancy up to 12 weeks gestation. Participants will be randomized 1/1 to 780 pump or standard of care (continue with current treatment of insulin pump without closed-loop or multiple daily insulin injections). Participants will be stratified according to study center, baseline Hba1c, and method of insulin delivery (pump or injections). Participants will be followed-up till delivery. To account for differences in the type of continuous glucose monitoring (CGM) used between the intervention group and the control group, the same CGM system as in the 780 insulin pump group (Guardian™ Sensor 3 and once available the Guardian 4 sensor) will be used in a blinded manner in the control group to collect CGM data during at least four different time points in pregnancy: at 14-17 weeks, 20-23 weeks, 26-29 weeks and 33-36 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | 780G | 780G closed-loop insulin delivery system (Medtronic) |
| DEVICE | standard of care | continue with standard of care treatment (pump without closed-loop or MDI) |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2023-04-30
- Completion
- 2023-05-10
- First posted
- 2020-08-20
- Last updated
- 2024-12-10
Locations
12 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT04520971. Inclusion in this directory is not an endorsement.